IntroductIon Chronic heart failure (HF) results from various disease processes. There are no data on the effect of the etiology of HF on the improvement after pacemaker upgrade.
IntroductIon Chronic heart failure (HF) with left bundle branch block is a result of various disease processes. Common causes of HF include ischemic heart disease, mainly cardiac muscle mass loss after myocardial infarction, inflammatory myocardial injury, or a progression of spontaneous cardiomyopathy.
The ischemic origin of HF distinguishes this type of cardiomyopathy (IC) from nonischemic cardiomyopathy (NIC) both etio logically and pathomorpho logically due to greater homogeneity and progression of coronary atherosclerosis. According to the Heart Failure Survival Score, which evaluates patients referred for consideration of
orIGInAL ArtIcLE
Influence of heart failure etiology on the effect of upgrading from right ventricular apical to biventricular or bifocal pacing in patients with permanent atrial fibrillation and advanced heart failure caused by the differences in the criteria for detecting cardiomyopathy types, duration of follow-up after CRT, and criteria for improvement.
All these studies were conducted in patients scheduled for CRT as the first electrotherapy procedure. Additionally, randomized studies of CRT to date have been almost exclusively restricted to patients in sinus rhythm. However, about 20% of the patients receiving CRT have permanent atrial fibrillation (AF). Patients suffering from AF constitute a particular subgroup within the population of patients with HF. 8 There are no data on the effect of HF etiology on the improvement after pacemaker upgrade in patients in whom HF developed in the course of apical right ventricular pacing and permanent AF.
We assessed changes in various para meters in patients with IC and NIC, pacemaker-dependent, with HF and permanent AF after upgrading from right ventricular apical pacing to biventricular pacing (BVP) or bifocal pacing (BFP) during 12-month follow-up.
PAtIEnts And mEthods
The study population consisted of 34 patients (8 women, 26 men), mean age 70.3 ±8.5 years, with chronic HF (New York Heart Association [NYHA] class III -28 patients and class IV -6 patients) and AF, and with right ventricular apical pacing (92.2 ±48.5 months; FIGurE 1) in whom upgrading to BFP (10 patients) or to BVP (24 patients) was performed. Patients had more than 95% ventricular pacing (spontaneous atrioventricular or postablation block -12 patients).
The inclusion criteria were as follows: 1) advanced systolic left ventricular failure, NYHA class III and IV, despite optimal pharmacotherapy of at least 3 months duration prior to qualification, 2) permanent AF, 3) spontaneous or postablative atrioventricular block leading to over 95% of circadian rhythm in heart stimulation, 4) right ventricular apical pacing.
All patients provided written informed consent for pacing system upgrade. The study was approved by the local ethics committee.
Initially, all patients were scheduled for left ventricular lead implantation, that is, for an upgrade from right ventricular apical pacing to BVP. In 10 BFP patients, due to the failure to cannulate the coronary sinus or the absence of vein allowing for efficient fixation of the left ventricular lead, and due to lack of consent for microthoracotomy, we decided to stimulate the upper septal part of the right ventricular outlet tract.
All patients scheduled for the inter vention received optimal individually-tailored pharmacotherapy. The percentage distribution of drugs used in the study population is presented in FIGurE 2.
The inclusion criteria, follow-up procedure, and additional examinations have been described elsewhere.
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In each patient who met the inclusion criteria, 12-lead electrocardiography, echocardiography, 6-minute walking test (6MWT), and the cardiac transplantation, ischemic etiology is one of the independent risk factors apart from QRS width ≥120 ms, low mean arterial blood pressure, low oxygen consumption during cardiopulmonary exercise testing, high heart rate, low sodium level, and low left ventricular ejection fraction (LVEF). 1 Small single-center and large population-based studies provide various data ranging from greater improvement after cardiac resynchronization therapy (CRT) in patients with NIC, 2-4 through no differences, 5, 6 to relatively more positive changes in patients with more advanced cardiomyopathy caused by ischemic disease with worse baseline prognosis in this type of cardiomyopathy.
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The differences in the study outcomes are probably In the remaining 5 patients, IC was diagnosed on the basis of medical records, physical examination, and additional tests (perfusion scintigraphy in 1 patient, coronary angiography in 1 patient, MSCT in 1 patient, transthoracic echocardiography in 2 patients). The NIC group included 9 patients.
The absence of visible lesions in the epicardial coronary arteries was confirmed by coronary angiography (n = 6) and MSCT (n = 3).
The 2 subgroups were compared with respect to the degree of improvement after pacemaker upgrade measured in absolute and relative terms at 6 and 12 months. A relative change in the parameter (∆P) was calculated according to the following formula:
where P 0 denotes the para meter measured during right ventricular apical pacing (baseline value), and P 1 the para meter measured at 6 or 12 months, i.e., during BFP or BVP.
A statistical analysis was performed using the STATISTICA package version 9.1 (StatSoft) and included descriptive statistics (minimum, maximum, mean, standard deviation) and the comparison of mean measurable para meters for independent samples using the Mann-Whitney U test, and sign test for dependent samples or the χ 2 test for categorical (qualitative) variables. measurement of brain natriuretic peptide (BNP) were performed.
The set of examinations was the same during the 12-month follow-up, in both 6-month stages.
The study population was further divided into those with IC and those with NIC. Ischemic etiology of advanced HF was confirmed in 25 patients, while nonischemic etiology in 9.
Criteria for the diagnosis of IC were as follows: previous myocardial infarction, previous myocardial revascularization, confirmation of coronary artery obstruction by coronary angiography, multislice computed tomography (MSCT), or fixed defect in perfusion scintigraphy, detection of segmental wall motion abnormalities by transthoracic echocardiography, and a history of anginal pain. Patients with coronary artery stenosis, anginal pain, and advanced left ventricular systolic failure were referred for invasive therapy and were excluded from the analysis.
Nonischemic etiology was confirmed if none of the IC criteria were met.
The IC group consisted of 25 patients of whom 20 had a history of myocardial infarction. These patients underwent a panel of diagnostic tests including coronary angiography (n = 12), MSCT (n = 5), or perfusion scintigraphy (n = 3). Four patients apart from coronary angiography had also MSCT, while 2 patients additionally underwent perfusion scintigraphy. Endpoint-free survival did not differ significantly in the mode of pacing (BVP in the IC group was 74% vs. 50% in the NIC group; P = 0.233). Changes in medication use at 6 and 12 months were nonsignificant (FIGurE 2).
The 2 groups were compared at 12 months taking into account only those free of endpoints (tAbLE 3) .
IC patients showed a significant improvement in the following para meters: NYHA class, LVEF, left ventricular dimension, mitral regurgitation, 6MWT, and QRS width (FIGurE 4) .
In the NIC group, NYHA class, QRS width, and LVEF were improved (FIGurE 4) .
At 12 months, IC patients showed a significantly greater degree of mitral regurgitation compared with NIC subjects despite the fact that there were no significant differences between the 2 subgroups before pacemaker upgrade. The IC group was larger than the NIC group and benefited from pacemaker upgrade, but had a greater hemo dynamic left ventricular injury at the end of follow-up. The McNemar's test was used to assess the significance of changes in medication use.
rEsuLts The 2 subgroups (IC and NIC) did not differ significantly at baseline (tAbLE 1). All patients completed the first 6 months of follow-up showing clinical improvement after pacemaker upgrade both when analyzed as the whole group or the 2 subgroups.
The IC group improved with respect to the NYHA class, LVEF, diastolic left ventricular dimension, mitral regurgitation degree, 6MWT, BNP levels, and QRS width (FIGurE 3) .
The NIC group showed a significant improvement in the NYHA class, LVEF, 6MWT, and QRS width (FIGurE 3) .
A comparison of the absolute values and the sum of relative para meter change in the 2 subgroups indicated a greater relative increase in LVEF at 6 months in the NIC group (tAbLE 2).
We assessed the effect of HF etiology on survival, clinical, and echocardiographic improvement at 12 months. The whole 12-month follow-up period was completed by a similar percent of IC and NIC patients (76% vs. 88.9%; P = 0.734). The study termination in the IC group was caused by sudden cardiac death (n = 1), death due to HF (n = 2), neuroFIGurE 3 Changes in the NYHA class, QRS duration, 6-minute walking test, brain natriuretic peptide level, left ventricular ejection fraction, mitral regurgitation, left ventricular end diastolic diameter, left ventricular end systolic diameter in the ischemic and nonischemic subgroups over a 6-month follow-up. The significance of changes was assessed using the sign test for dependent samples. In the box plot, the range (standard error) is represented by whiskers. The mean is represented by point in the middle of the whiskers. Abbreviations: see tAbLE 1 tAbLE The analysis of CARE-HF suggests that the long-term effects of CRT on symptoms, morbidity, and mortality are similar in patients with IC and NIC. These benefits were observed even though IC patients had worse overall prognosis. 7 Moreover, the 3-year MADIT-CRT study in patients with moderate HF showed differences in the prognostic value of risk factors relating to worsening HF or death between cardiomyopathy types with a 45% increase in the total risk associated with cessation of CRT in the IC group. 13 In the present study, we evaluated a different population of patients with cardiac remodeling in the course not only of IC and NIC but also long-term right ventricular apical pacing with permanent AF. Upgrade procedure was individually determined by the course of cardiac veins, but the study subgroups did not differ significantly in the mode of pacing system.
In the NIC group, pacemaker upgrade induced more favorable changes in ventricular remodeling: greater improvement in LVEF at 6 months, and greater reduction of mitral regurgitation at 12 months. The present study corroborates the findings of other investigators that cardiomyopathy groups differ in the process of remodeling after CRT.
dIscussIon Straburzynska-Migaj et al.
10 demonstrated differences in the significance of QRS broadening induced by the left bundle branch block depending on the type of cardiomyopathy. In IC, unlike in NIC, the broadening of QRS complex was not a marker of significant myocardial injury. Peichl et al. 11 studied electrical propagation in the left bundle branch block and showed the variation of the propagation vector in patients with IC and myocardial infarction. These findings indicate that the significance of electrical dyssynchrony in the left bundle branch block depends on the type of cardiomyopathy. There was also a study on the effect of postinfarct scar on propagation delay in the heart muscle during pacing. 12 Varying responses to CRT, depending on the type of cardiomyopathy, were also observed on echocardiography showing the regression of ventricular remodeling only during late follow-up. Short-term studies did not demonstrate any differences. 6 The MIRACLE study showed even later reversal of changes in certain echocardiographic para meters, which improved within the first 6 months after CRT in the IC group.
4 This was not equivalent to differences in clinical outcomes. As demonstrated in the prolonged 18-month follow-up in the MIRACLE study, the clinical benefit (quality of life, NYHA class, 6MWT) were similar in the IC and NIC groups. FIGurE 4 6-minute walking test, brain natriuretic peptide level, left ventricular ejection fraction, mitral regurgitation, left ventricular end diastolic diameter, left ventricular end systolic diameter in the ischemic and nonischemic subgroups over a 12-month follow-up. The significance of changes was assessed using the sign test for dependent samples. In the box plot, the range (standard error) is represented by whiskers. 
